Doseology Taps Retail Pharmacy Veteran as Executive Chairman
Event summary
- Larry Latowsky appointed Executive Chairman of Doseology Sciences on February 18, 2026
- Granted 4,000 RSUs (vesting over 36 months) and 6,000 PSUs (performance-based)
- Latowsky previously led Katz Group Canada's C$3B acquisition by McKesson
- Doseology focuses on precision-controlled oral stimulant delivery systems
- Company emphasizes harm-reduction principles and intellectual property development
The big picture
Doseology's appointment of Latowsky signals confidence in the timing of the oral stimulant category and the company's ability to execute. His background in scaling retail pharmacy operations and navigating institutional transactions positions Doseology to strengthen its governance and strategic decision-making as it moves toward commercialization. The company is betting on disciplined execution and network-driven partnerships to capture a fragmented North American market.
What we're watching
- Governance Dynamics
- How Latowsky's retail pharmacy experience will shape Doseology's governance and capital-markets strategy
- Market Timing
- Whether Doseology can capitalize on the emerging oral stimulant category in North America
- Execution Risk
- The pace at which Doseology can transition from early innovation to broader commercialization